CEO for CymiraBio
Cancer remains a leading cause of death worldwide, despite significant advances in treatment. A key challenge in cancer therapy lies in addressing cancer stem cells (CSCs), which are responsible for driving metastasis, recurrence, and drug resistance. Developing effective treatments targeting CSCs is crucial but complex, due to the difficulty in identifying unique therapeutic targets. The ability to successfully target and eliminate CSCs can revolutionize cancer treatment, potentially halting tumor growth and preventing cancer recurrence.
CymiraBio addresses this problem by developing a first-in-class protein drug conjugate that shows promise in the reduction and control of tumor growth, with favorable pharmacokinetics and pharmaceutical properties.
The Invention
The groundbreaking research originates from the pioneering work of Dr. Stephen Howell, backed by the Clayton Medical Research Foundation, which, along with its supported and supporting entities, funds and conducts medical research in the U.S. and Switzerland leading to cutting-edge biomedical technologies, several of which have been licensed to biotech companies and translated into impactful therapeutics products. This novel approach uses the natural ligand for stem cell receptors LGR4LGR5 and LGR6 to deliver cytotoxins and kill cancer stem cells. It has already demonstrated significant anti-tumor activity in preclinical models for colorectal, ovarian, and gastric cancers.
The position of CEO
We are seeking a visionary CEO to lead CymiraBio into its next pivotal phase of growth. Backed by NLC and working closely with the inventor, Dr. Stephen Howell a seasoned medical oncologist and biotech expert—along with other strategic partners, the CEO will play a key role in driving the company's future success.
Responsibilities include:
- Securing non-dilutive and dilutive funding.
- Building a strong strategy around the beachhead indication.
- Overseeing preclinical research and IND-enabling studies.
- Building and leveraging networks with investors, pharma, and oncology KOLs to support growth.
- Forming strategic partnerships with CROs, pharma, and other key stakeholders to advance clinical development.
- Leading the company towards Phase I clinical trials.
- Being on top of oncology trends to guide decision-making and ensure strategic alignment.
Your Profile
You are highly motivated to transform patients' lives by revolutionizing cancer treatment and have:
- A proven track record in biotech fundraising, especially for preclinical stage assets.
- Experience in preclinical drug development, IND-enabling studies, and early-stage clinical trials, ideally with a background in ADCs or biologics.
- A strong network in oncology, including connections with key opinion leaders (KOLs), clinical experts, and potential partners.
- Knowledge of and connections with relevant CROs and CDMOs, ensuring access to the right expertise.
The opportunity
We offer the unique opportunity to an entrepreneur or executive with entrepreneurial ambition to come on board as a co-founder in a highly promising venture. The participation package includes:
- Equity-based remuneration
- Cash compensation tied to successful funding of the company
- The opportunity to co-fund at a favorable terms
As a NLC venture CEO you will have access to the expertise and network of the entire NLC ecosystem including the use of NLC Venture Services and of course you’ll join the supportive group of CEO’s leading our other (100+) ventures.
Last but not least
As a CEO for CymiraBio, you will have the unique opportunity to lead the cutting-edge biotech company developing novel therapeutics that target cancer stem cells, an area with high unmet medical need. Our platform has the potential to revolutionize cancer treatment by overcoming resistance and preventing tumor recurrence. If you are passionate about driving groundbreaking innovation in oncology and making a significant impact on patients' lives, we invite you to join us.
If you have any questions please contact Augusta Poteliunaite, [email protected]
